PROGRAM SNAPSHOT

Sernova Biotherapeutics — Cell Pouch

🚀 Pack Leader Company-Reported

A donor-islet implant device reporting multi-year islet survival — with one detail still unconfirmed.

What's actually shown: Phase 1/2 ongoing with donor islets in the current cohort; a separate iPSC-derived arm with Evotec is planned but not yet running. Reported islet survival of 1-5+ years and insulin-independence support “following protocol-specified treatment.” Immunosuppression regimen not stated in the release reviewed — not claiming immunosuppression-free until confirmed.

Last verified: 2026-08-24. Sources: Sernova press release.

This is a Program Snapshot, not yet a full Trial Report Card — a full Report Card means the deeper eligibility, risk, and enrollment research we do for each Cure Radar post. Follow @t1dcureintelligence for the full breakdown when this program gets its own deep-dive.

← Back to the full leaderboard